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A B S T R A C T
Background: Hepatitis E virus (HEV) genotype 3 is endemic in Europe, and the infection is mostly
subclinical or acute and self-limiting. However, persistent infection is described among HIV-infected
individuals. The prevalence of antibodies against HEV (anti-HEV) among HIV-infected persons varies
geographically and is unknown in Denmark. Rates of co-infection with HEV among HIV-infected
individuals in Denmark over three decades, from the early 1980s to 2013, were investigated.
Methods: A total of 2506 HIV-infected persons were investigated from two cohorts followed at Hvidovre
Hospital, Denmark. Blood samples were tested retrospectively for anti-HEV, including samples from 2216
persons who were enrolled in a prospective clinical cohort and followed between 1995 and 2013, as well
as samples from 290 persons from a historical cohort followed between 1980 and 1994. For anti-HEV
seroconverting individuals, serial samples were tested for HEV RNA. Factors associated with anti-HEV
status were explored using multivariable logistic regression analysis.
Results: The overall HEV seroprevalence rates were stable during the 1980s,1990s, and 2000–2013 (23.1%,
22.9%, and 23.7%, respectively). In all decades, rates of anti-HEV increased with older age, and anti-HEV
seropositivity was associated with older generations, HIV risk group, and geographic origin. Persistent
HEV infection was not detected in any of 57 individuals with anti-HEV seroconversion.
Conclusions: HEV seroprevalence rates were stable in HIV-infected individuals from the early 1980s to
2013. Rates increased with age. No evidence of persistent HEV infection was detected. Infection with HEV
is frequent, but persistent HEV infection is rare among HIV-infected individuals.
© 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Hepatitis E virus (HEV) genotype 3 (gt3) is endemic in Europe
and other industrialized countries, and an increased focus has been
placed on infection with this agent over the last decades (Kamar
et al., 2014). HEV-gt3 has a zoonotic and mainly porcine reservoir,
and the predominant route of transmission is believed to be
foodborne (Kamar et al., 2012; Van der Poel, 2014). Parenteral
transmission via blood transfusion and organ transplantation has
also been reported (Schlosser et al., 2012; Hewitt et al., 2014). HEV-* Corresponding author at: Department of Clinical Immunology, Rigshospitalet,
Copenhagen University Hospital, Blegdamsvej 9, 2100 Ø, Copenhagen, Denmark.
E-mail address: lene.holm.harritshoej@regionh.dk (L.H. Harritshøj).
https://doi.org/10.1016/j.ijid.2019.04.029
1201-9712/© 2019 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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However, persistent infection with HEV-gt3 that might lead to
chronic HEV infections has been reported in patients after organ
transplantation, in patients with haematological disorders treated
with chemotherapy, and among HIV-infected individuals (Dalton
et al., 2009; Colson et al., 2011; Kamar et al., 2013). Studies on the
prevalence of HEV antibodies (anti-HEV) in HIV-infected individ-
uals vary among geographical areas (Debes et al., 2016). The
reported prevalence of anti-HEV in HIV-infected individuals was
2.6% in Switzerland, 9% in the UK, 21% in Spain, and 37.8% in France
(Abravanel et al., 2017; Kenfak-Foguena et al., 2011; Keane et al.,
2012; Mateos-Lindemann et al., 2014). The prevalence of HEV
immunoglobulin G (IgG) among healthy Danish blood donors
declined from 32.9% in 2003 to 10–19.3% in 2013 (Christensen et al.,
2008; Holm et al., 2015).ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
hagen from ClinicalKey.com by Elsevier on November 14, 2019.
. Copyright ©2019. Elsevier Inc. All rights reserved.
Figure 1. Flow charts for the study cohort.
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Denmark is unknown. The primary aim of this study was to
estimate the prevalence of anti-HEV IgG among HIV-infected
patients over three decades: the early 1980s, 1990s, and 2000–
2013. Secondary aims included an assessment of factors associated
with the presence of anti-HEV IgG and the presence of persistent
HEV infection in HIV-infected patients.
Materials and methods
Subjects and samples
Patients eligible for the current study were any individual
attending the Department of Infectious Diseases, Hvidovre
Hospital and under active follow-up from January 1, 1995 to
May 30, 2013. All patients were followed prospectively as part of an
ongoing nationwide Danish HIV cohort study (Obel et al., 2009).
New referrals were continuously enrolled into the cohort. Blood
samples were drawn at clinic visits and plasma or serum was
stored at 80 C.
Additional samples from individuals who had attended the
clinic in the early 1980s but who had died before 1995 were
retrieved from a repository and served as a historical cohort of HIV-
infected patients before the era of antiretroviral treatment.
The study was approved by the local ethics committee for the
Capital Region of Denmark (No. H-18045809) and the Danish Data
Protection Agency (No. 2007-41-1634).
Testing strategy
For individuals in both cohorts, the most recent available
serum or plasma sample was tested for anti-HEV IgG.
Individuals with anti-HEV IgG-positive results in their latest
sample were subsequently tested for anti-HEV IgG in their ﬁrst
available archived sample. For patients with an anti-HEV
seroconversion pattern between their ﬁrst and most recent
sample, additional intermediate samples were identiﬁed to
detect the time of seroconversion. Further, serial samples close
to and within 3–12 months before anti-HEV seroconversion
were tested for HEV RNA.
Anti-HEV ELISA
HEV antibodies were detected using the Wantai HEV IgG ELISA
assay (Nordic BioSite, Copenhagen, Denmark), in accordance with
the manufacturer’s instructions; a signal/cut-off (S/CO) ratio of
1.1 was used to indicate a positive result.
HEV RNA detection
Detection of HEV RNA was done using a CE-marked qualitative
nucleic acid ampliﬁcation test (NAT) (Procleix HEV Assay; Grifols
Diagnostic Division, Emeryville, CA, USA) with a 95% detection
probability of 7.9 IU/ml and a speciﬁcity of 99.95%.
Conﬁrmation of HEV RNA reactivity and genotyping
Initial HEV RNA NAT-positive reactions were conﬁrmed by
diagnostic real-time PCR amplifying a 79-bp fragment of ORF-3
(Jothikumar et al., 2006). RNA was extracted using the MagNa Pure
LC Total Nucleic Acid Isolation Kit on a MagNa Pure 96 instrument
(Roche Diagnostics, Rotkreuz, Switzerland) prior to PCR. Further
PCR ampliﬁcation was attempted for the purposes of genotyping
using previously described methods (Midgley et al., 2014; Hogema
et al., 2016).Downloaded for Anonymous User (n/a) at BS - University of Copen
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Values are presented as the median with interquartile range
(IQR) or range. Differences were tested using the Chi-square test or
Mann–Whitney test, as appropriate.
Follow-up time was calculated from the time of the ﬁrst
available sample to the latest sample analysed. The incidence rate
was calculated from anti-HEV seroconverting patients. For patients
who seroconverted, the time to seroconversion was considered
half way between the closest negative and positive anti-HEV IgG
test.
Factors associated with anti-HEV IgG positivity at baseline or
seroconversion during follow-up were studied by multivariable
logistic regression analysis and presented as an odds ratio (OR)
with 95% conﬁdence interval (CI) among the Hvidovre Hospital
clinic cohort.
Persistent HEV infection was deﬁned as HEV viremia in two or
more samples taken at least 3 months apart.
HEV seroprevalence rates were calculated among newly
enrolled patients in the cohorts by using time-points of the ﬁrst
available positive anti-HEV IgG result and the ﬁrst available
negative anti-HEV IgG result, with the assumption that anti-HEV
IgG-negative patients had never been anti-HEV IgG-positive. This
assumption may be justiﬁed if the mean time between the latest
and ﬁrst samples of anti-HEV-negative patients is limited;
otherwise there is a risk of underestimating the true seropreva-
lence rates, as the level of anti-HEV declines over time. HEV
seroprevalence rates were calculated for three time periods: the
1980s, the 1990s, and 2000–2013.
The statistical analyses were performed using IBM SPSS
Statistics version 22 (IBM Corp., Armonk, NY, USA).
Results
Figure 1 shows ﬂow charts of the two study cohorts, which
included a total of 2506 individuals: 2216 patients under active
follow-up and 290 individuals from the historical cohort. In total,
584 (23.3%) individuals were anti-HEV IgG-positive in their most
recent sample. Of these, an earlier sample was retrieved for 413
individuals, and 336 samples were also anti-HEV IgG-positive at
this time-point. Among the 77 individuals with discordant tests, a
total of 276 serial samples between the two time-points were
available for 57 individuals. The median interval between the ﬁrst
available sample and the tested (latest) sample was 7 years (IQR 3–
13 years) for the anti-HEV IgG-negative patients. Among the
patients with anti-HEV IgG-positive results, the median S/CO
declined from 7.94 (IQR 3.48–12.23) in the ﬁrst available samples
to 6.74 (IQR 2.85–11.67) in the second samples, over a median
interval of 8 years (IQR 4–13 years).hagen from ClinicalKey.com by Elsevier on November 14, 2019.
. Copyright ©2019. Elsevier Inc. All rights reserved.
Table 1
Characteristics of HIV-infected individuals included in the prospective Hvidovre Hospital clinic cohort.
Anti-HEV IgG-positive
n = 415
18.7% (CI 17.2–20.4%)
Anti-HEV IgG-negative
n = 1801
81.3% (CI 79.6–82.8%)
p-Value
Age (years), median (IQR) 40 (33–48) 34 (28–41) 0.0001
Male sex, n (%) 313 (75.4%) 1339 (74.4%) 0.66
CD4 T-cell count (cells/ml), median (IQR) 280 (122–470) (n = 343) 296 (146–478) (n = 1467) 0.48
Antiretroviral therapy 34 (9.8%) 176 (8.2%) 0.32
Route of HIV transmission, n (%)
HSX 146 (35.2%) 610 (34.2%)
IDU 76 (18.3%) 250 (14.0%)
MSM 164 (39.5%) 842 (47.1%)
Other or unknowna 29 (7.0%) 84 (4.7%) 0.007
Country of origin, n (%)
Europe 338 (81.6%) 1389 (77.4%)
America 2 (0.5%) 38 (2.1%)
Africa 42 (10.1%) 246 (13.7%)
Asia 27 (6.5%) 85 (4.7%)
Greenland 3 (0.7%) 26 (1.4%)
Other/unknown 2 (0.5%) 11 (0.6%) 0.03
HEV, hepatitis E virus; IgG, immunoglobulin G; CI, conﬁdence interval; IQR, interquartile range; HSX, heterosexual; IDU, injection drug use; MSM, males who have sex with
males.
a Other routes of HIV transmission include perinatal infection and transfusion transmission.
Table 2
Factors associated with anti-HEV immunoglobulin G positivity in the prospective
Hvidovre Hospital clinic cohort at cohort entry.
Variable Multivariable OR (95% CI) p-Value
Birth cohort
1970– 1.0
1950–69 5.05 (3.44–7.41) 0.0001
>1950 1.96 (1.43–2.68) 0.0001
Route of HIV transmission category
HSX 1.0
IDU 1.29 (0.91–1.82) 0.15
MSM 0.72 (0.54–0.94) 0.02
Other or unknowna 1.27 (0.79–2.05) 0.33
Country of origin
Europe 1.0
America 0.32 (0.08–1.33) 0.12
Africa 0.84 (0.57–1.25) 0.39
Asia 1.65 (1.02–2.67) 0.04
Greenland 0.55 (0.16–1.84) 0.33
Other/unknown 0.87 (0.18–4.10) 0.86
HEV, hepatitis E virus; IgG, immunoglobulin G; HSX, heterosexual; IDU, injection
drug use; MSM, males who have sex with males; CI, conﬁdence interval.
a Other routes of HIV transmission include perinatal infection and transfusion
transmission.
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Patient characteristics are shown in Table 1. Brieﬂy, among 2216
individuals, 415 (18.7%) were anti-HEV IgG-positive at their earliest
available test. Anti-HEV IgG-positive individuals were older and
more likely to be from Europe or Asia. There were more individuals
who had acquired HIV through injection drug use (IDU) and fewer
males who have sex with males (MSM) who were anti-HEV IgG-
positive. Neither CD4 T-cell count within 90 days of sampling nor
the use of antiretrovirals at the time of sampling was associated
with anti-HEV IgG status. By multivariable logistic regression
analysis, individuals born after 1970 compared to before 1970 and
MSM compared to individuals with heterosexual (HSX) HIV
transmission were less likely to be anti-HEV IgG-positive.
Additionally, individuals from Asia compared to Europe were
more likely to be anti-HEV IgG-positive (Table 2).
The follow-up time was not available for 19 of the 1801
individuals without anti-HEV IgG at baseline. Of the remaining
1782 individuals, 37 seroconverted during the 15 836 years of
follow-up, corresponding to an incidence rate of 2.34 cases (95% CI
1.67–3.19) per 1000 person-years. The median time to serocon-
version from enrolment was 307 days (range 28–946 days). Age,
sex, route of HIV transmission, and country of origin were not
associated with seroconversion (data not shown).
Historical cohort
Of the 290 individuals, 20 (6.9%) were female and 132 (45.5%)
were anti-HEV IgG-positive. Samples were collected between 1980
and 1994. The median age at the time of testing was 34 years (IQR
28–41 years).
HEV RNA
A total of 276 serial samples from 57 anti-HEV seroconverting
individuals (37 from the clinic cohort and 20 from the historical
cohort) were analysed for HEV RNA. Only one sample from an
individual included in the Hvidovre Hospital clinic cohort was HEV
RNA NAT reactive, which was conﬁrmed by a second PCR (index
sample). Samples drawn 3, 12, and 13 weeks before and 9 weeks
after the index sample all tested HEV RNA-negative, showing no
evidence of a persistent HEV infection. Anti-HEV IgG was ﬁrst
detected 3 weeks before the index sample, and the S/CO ratioDownloaded for Anonymous User (n/a) at BS - University of Copenhag
For personal use only. No other uses without permission. Cincreased with the subsequent samples tested. Anti-HEV IgM was
only weakly positive (S/CO 2.3) in one sample taken 9 weeks after
the index sample.
This individual was a 38-year-old male of Danish origin on a
three-drug antiretroviral regimen with a CD4 T-cell count >200
cells/ml (nadir CD4 T-cell count 205 cells/ml at the time of the index
sample to 299 cells/ml 9 weeks later), who had acquired HIV
infection through sex with men. Liver enzymes were slightly
elevated both prior to and after anti-HEV seroconversion, and the
patient notes did not indicate a symptomatic HEV infection. The
level of HEV RNA was below the limit for further characterization
by sequencing.
Anti-HEV IgG prevalence by decade, age group, and year of birth
Anti-HEV IgG seroprevalence rates for newly enrolled patients
in the cohorts and calculated from the results of the ﬁrst available
sample categorized in time periods of the 1980s, the 1990s, and
2000–2013 were 23.1%, 22.9%, and 23.7%, respectively (p = 0.89)
(Figure 2). By stratifying patients into 10-year age groups, a gradualen from ClinicalKey.com by Elsevier on November 14, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
Figure 2. Prevalence of anti-hepatitis E virus immunoglobulin G by decade and
age-group.
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youngest to the oldest patients in all three decades (p < 0.003 for
each decade). There was a tendency, although statistically non-
signiﬁcant, towards a decreasing anti-HEV prevalence rate from
the 1980s to the latest decade in all age groups, except for an
opposite tendency in the youngest age group of 16–25 years
(Figure 2).
By plotting the frequency of anti-HEV positivity by birth decade,
a signiﬁcant decrease in anti-HEV IgG positivity was found for HIV-
infected patients born in later birth decades (p < 0.00001) (Figure
3). With very few individuals in the cohorts being born in the 1910s
(n = 2) and the 1990s (n = 12) and none of them being anti-HEV-
positive, no data are visualized in the ﬁgure for these birth decades.
Discussion
In this study, a high but overall stable prevalence rate of anti-
HEV IgG by time close to enrolment was found in two cohorts of
HIV-infected patients, with rates of 23.3%, 22.8%, and 23.8% over
three decades from the early 1980s, the 1990s, and 2000–2013,
respectively.
In all three decades, the HEV seroprevalence rate increased with
increasing age and the odds of being anti-HEV-positive were
higher in older generations compared to individuals in the younger
birth cohorts. MSM had lower odds of being anti-HEV-positive
compared to HSX. Additionally, no persistent HEV infections were
found in serial samples from anti-HEV seroconverting patients
living with HIV.
HEV seroprevalence rates among HIV-infected individuals vary
widely between geographical areas, from 2.9% in Switzerland to
37.8% in France (Debes et al., 2016; Abravanel et al., 2017). A
comparison of seroprevalence studies using different anti-HEV IgG
assays should be interpreted with caution because the sensitivityFigure 3. Frequency (%) of anti-hepatitis E virus immunoglobulin G positivity by
birth decade.
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from Wantai used in the current study was selected because
studies have shown it to have higher sensitivity and speciﬁcity
than other assays, even when testing immunocompromised
patients (Abravanel et al., 2013; Pas et al., 2013).
The increasing presence of anti-HEV IgG with age can be
explained by the cumulative exposure to HEV over time, as
foodborne exposure is supposedly the main transmission route of
HEV, whether HIV-infected or not.
A study of anti-HEV seroprevalence among healthy blood
donors in Denmark in 2013 that also used the Wantai assay,
showed a similar high rate and increase with age of anti-HEV, with
a prevalence rate of 19.8% among the blood donors (Holm et al.,
2015). This is comparable to the result of 23.8% among HIV-
infected individuals in the decade spanning 2000–2013 in the
present study. This ﬁnding of similar HEV seroprevalence among
HIV-infected patients and blood donors is in concordance with
case–control studies showing that the HEV seroprevalence rate
among HIV-infected individuals is not higher than the rate among
non-HIV-infected individuals. Keane et al. found an HEV seroprev-
alence of 9.4% in the HIV-infected population, which was not
signiﬁcantly different from age and sex-matched controls of non-
HIV-infected patients, in whom the HEV seroprevalence rate was
13.8% (Keane et al., 2012). Abravanel et al. (2017) even found a
signiﬁcantly lower level of HEV seroprevalence among HIV-
infected persons (38.7%) in France, when compared to age and
sex-matched blood donors (47.3%) from the same geographical
area (Abravanel et al., 2017).
Although the HEV seroprevalence rates in the current study did
not, in general, decline over the decades, as shown in previous
studies of Danish blood donors, a decreasing tendency of anti-HEV
positivity was found in most age groups of HIV-infected individu-
als.
HEV seroprevalence studies among healthy Danish blood
donors from 1983, 2003, and 2013 showed decreasing seropreva-
lence rates of 32.9%, 20%, and 10.7%, respectively, when using the
same anti-HEV IgG assay from the National Institutes of Health,
USA (Christensen et al., 2008; Holm et al., 2015).
In the blood donor study by Christensen et al., a cohort effect
could explain the decreasing results of HEV seroprevalence rates,
with donors born after 1945 having a lower degree of exposure to
HEV compared to donors born before 1945. This was also reﬂected
among the HIV-infected individuals in Denmark in the current
study, where the frequency of anti-HEV positivity was signiﬁcantly
higher among older generations compared with generations born
later. This result could also indicate a cohort effect, where earlier
generations had been more exposed to HEV than later generations.
In the assessment of factors associated with the presence of
anti-HEV IgG, older generation, HIV transmission route, and
country of origin were signiﬁcantly associated with anti-HEV
IgG at baseline in multivariable logistic regression analyses of the
prospective HIV cohort.
Individuals of Asian descent showed a higher likelihood of anti-
HEV IgG positivity compared to those of European descent. This
could be due to exposure to both the zoonotic and the obligate
human HEV genotypes (gt1 and gt2), as the latter are more
widespread in Asia (Van der Poel, 2014).
MSM have a higher risk of viral hepatitis infections including
hepatitis A virus (HAV), hepatitis B virus (HBV), and hepatitis C
virus (HCV) through sexual exposure (Kahn, 2002). In the present
study, individuals who reported MSM as a likely source of HIV
transmission were less likely to be anti-HEV-positive. The results
indicate that HEV is not primarily sexually transmitted and
contradict other studies that have shown MSM to be at increased
risk of anti-HEV positivity regardless of HIV status, which was
believed to be due to sexual practices with faecal–oralhagen from ClinicalKey.com by Elsevier on November 14, 2019.
. Copyright ©2019. Elsevier Inc. All rights reserved.
L.H. Harritshøj et al. / International Journal of Infectious Diseases 84 (2019) 67–72 71transmission (Payne et al., 2013; Montella et al.,1994). Results from
other association studies on HIV infection risk factors and HEV
have previously found no association between HIV risk groups and
HEV (Kenfak-Foguena et al., 2011; Pineda et al., 2014).
The zoonotic HEV genotypes – especially HEV-gt3 – are
endemic in industrialized countries such as Denmark. The ﬁnding
of high HEV seroprevalence rates and few cases of clinical HEV
infection suggests that subclinical and self-limiting infections are
common. HEV-gt3 may cause chronic or persistent infections
among immune deﬁcient patients, including cases described in
HIV-infected individuals (Dalton et al., 2009; Colson et al., 2011). In
the current study, no sign of persistent HEV infection was found
among individuals for whom a time of seroconversion could be
estimated. Of note, HEV RNA was only detected in a single sample
from 276 specimens serially sampled around the time of
seroconversion in 57 individuals. Of these, 37 individuals were
treated in the era of antiretrovirals and 20 individuals were not
treated and were therefore presumably more profoundly immune
deﬁcient.
The study ﬁndings conﬁrm that persistent HEV infection is a
rare event among HIV-infected patients. In a Spanish prospective
study of 849 HIV-infected individuals, no chronic HEV infections
were detected despite transient detection of HEV RNA among 5.7%
of the investigated population and an anti-HEV prevalence of 9.8%
(Rivero-Juarez et al., 2015). A retrospective study in the USA among
194 HIV-infected military beneﬁciaries with acute liver enzyme
elevation (between 1985–2009) found no patients with persistent
HEV viremia, and only one patient with transient HEV RNA was
detected (Crum-Cianﬂone et al., 2012).
A study among 735 HIV cohort participants in Switzerland
detected prolonged HEV viremia in two HIV-infected patients with
liver enzyme elevation; both patients had low CD4 counts of <150
CD4 cells/ml (Kenfak-Foguena et al., 2011).
This study has strengths and limitations. First, the study is one
of the largest investigations of HEV infection in HIV-infected
individuals, with more than 2500 patients examined. Furthermore,
this is the ﬁrst study of HEV among Danish HIV-infected patients. A
limitation of the study is the risk of underestimating the HEV
seroprevalence results, as it was assumed that patients with a
negative anti-HEV IgG result in the most recent sample were
seronegative in their ﬁrst available sample by enrolment in the
cohort. The period of detectable anti-HEV IgG levels after naturally
acquired HEV infection is unknown, as most infections are
subclinical. Su et al. described a steady decline of anti-HEV IgG
levels over time and independent of the initial antibody level and
predicted that 50% would be undetectable after 14.5 years (Su et al.,
2017). The median follow-up interval of the anti-HEV-negative
patients, i.e. from cohort entry to the latest available sample, was 7
(IQR 3–13) years. Therefore, it is possible that some individuals
may have had anti-HEV IgG levels that declined below the limit of
detection over time. However, using the S/CO ratio as a
measurement of the anti-HEV titre showed a modest decline in
the S/CO ratio over 8 years, supporting the assumption that the
earliest available test likely would be negative if the latest available
test was negative.
Another limitation is the risk of underestimating persistent HEV
infections due to the testing strategy for detecting persistent
viremia among patients who eventually seroconverted to anti-HEV
IgG. This strategy could have excluded patients with a poor
immunological status, who are not able to produce detectable HEV
antibodies. Thus, with the testing strategy used, the rate of
persistent infections could only be detected among the HIV-
infected individuals who had anti-HEV seroconverted.
In conclusion, this study found a high HEV seroprevalence rate
of 23% among newly enrolled HIV-infected individuals in two
Danish cohorts from the early 1980s to 2013. The HEVDownloaded for Anonymous User (n/a) at BS - University of Copenhag
For personal use only. No other uses without permission. Cseroprevalence rate increased with older age, and anti-HEV
positivity was associated with birth cohort, HIV risk group, and
geographical origin. No evidence of persistent HEV infection in
HIV-infected individuals was found, either before or after the era of
effective antiretroviral treatment for HIV.
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